However, prognostic studies for the other candidate genes require the development of new antibodies (C17orf39, RICH2, RASD1) or testing of available antibodies on osteosarcoma tissues (TOP3A, COPS3, SHMT1, PRPSAP2, PMP22), which is presently underway. This evidence concerns the gene PRPSAP2 and osteosarcoma.